Self-Performed Dietary Sodium Reduction and Blood Pressure in Patients With Essential Hypertension: A Randomized Clinical Trial von Duus, Camilla Lundgreen, Nielsen, Steffen Flindt, Hornstrup, Bodil Gade, Mose, Frank Holden, Bech, Jesper Nørgaard

Volltext

Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (S... von Nielsen, Steffen Flindt, Duus, Camilla Lundgreen, Buus, Niels Henrik, Bech, Jesper Nørgaard, Mose, Frank Holden

Volltext

2500 Renal perfusion and SGLT2i von Nielsen, Steffen Flindt, Duus, Camilla, Buus, Niels Henrik, Bech, Jesper Noergaard, Mose, Frank

Volltext

6650 SGLT2-INHIBITION IMPROVES VASCULAR FUNCTION IN TYPE 2 DIABETES: A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED CROSSOVER TRIAL von Kristensen, Didde Kidmose, Nielsen, Steffen Flindt, Buus, Niels Henrik, Duus, Camilla, Mårup, Frederik, Bech, Jesper, Mose, Frank

Volltext

SGLT2 inhibition improves endothelium-independent vasodilatory function in type 2 diabetes: A double-blind, randomized, placebo-controlled crossover trial von Kristensen, Didde Kidmose, Mose, Frank Holden, Buus, Niels Henrik, Duus, Camilla Lundgreen, Mårup, Frederik Husum, Bech, Jesper Nørgaard, Nielsen, Steffen Flindt

Volltext

Randomized, Placebo-Controlled Trial on the Renal and Systemic Hemodynamic Effects of Empagliflozin von Nielsen, Steffen Flindt, Duus, Camilla Lundgreen, Buus, Niels Henrik, Bech, Jesper Nørgaard, Mose, Frank Holden

Volltext

Empagliflozin in type 2 diabetes with and without CKD and non-diabetic CKD: Protocol for 3 randomized, double-blind, placebo controlled cross-over trials von Nielsen, Steffen Flindt, Duus, Camilla Lundgreen, Buus, Niels Henrik, Bech, Jesper Nørgaard, Mose, Frank Holden

Volltext